Reviews - 4i3l mentioned but not cited (1)
- Recent advances of IDH1 mutant inhibitor in cancer therapy. Tian W, Zhang W, Wang Y, Jin R, Wang Y, Guo H, Tang Y, Yao X. Front Pharmacol 13 982424 (2022)
Articles - 4i3l mentioned but not cited (3)
- Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. Zheng B, Yao Y, Liu Z, Deng L, Anglin JL, Jiang H, Prasad BV, Song Y. ACS Med Chem Lett 4 542-546 (2013)
- Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. Liu Z, Yao Y, Kogiso M, Zheng B, Deng L, Qiu JJ, Dong S, Lv H, Gallo JM, Li XN, Song Y. J Med Chem 57 8307-8318 (2014)
- Apo2ph4: A Versatile Workflow for the Generation of Receptor-based Pharmacophore Models for Virtual Screening. Heider J, Kilian J, Garifulina A, Hering S, Langer T, Seidel T. J Chem Inf Model 63 101-110 (2023)
Reviews citing this publication (10)
- Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. Wong CC, Qian Y, Yu J. Oncogene 36 3359-3374 (2017)
- Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. Ye D, Guan KL, Xiong Y. Trends Cancer 4 151-165 (2018)
- Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer. Akins NS, Nielson TC, Le HV. Curr Top Med Chem 18 494-504 (2018)
- Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development. Dang L, Su SM. Annu Rev Biochem 86 305-331 (2017)
- Metabolic consequences of oncogenic IDH mutations. Parker SJ, Metallo CM. Pharmacol Ther 152 54-62 (2015)
- Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. Song Y, Wu F, Wu J. J Hematol Oncol 9 49 (2016)
- Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. Madala HR, Punganuru SR, Arutla V, Misra S, Thomas TJ, Srivenugopal KS. Cancers (Basel) 10 E49 (2018)
- Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. Clark PM, Mai WX, Cloughesy TF, Nathanson DA. Curr Neurol Neurosci Rep 16 17 (2016)
- Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. Chen C, Wang Z, Qin Y. Front Pharmacol 13 935536 (2022)
- The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. Liu Y, Xu W, Li M, Yang Y, Sun D, Chen L, Li H, Chen L. Acta Pharm Sin B 13 1438-1466 (2023)
Articles citing this publication (33)
- Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery. Merk A, Bartesaghi A, Banerjee S, Falconieri V, Rao P, Davis MI, Pragani R, Boxer MB, Earl LA, Milne JLS, Subramaniam S. Cell 165 1698-1707 (2016)
- New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U. Nat Chem Biol 11 878-886 (2015)
- Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, Sahm F, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Panknin O, Rehwinkel H, Zimmermann K, Hillig RC, Guenther J, Toschi L, Neuhaus R, Haegebart A, Hess-Stumpp H, Bauser M, Wick W, Unterberg A, Herold-Mende C, Platten M, von Deimling A. Acta Neuropathol 133 629-644 (2017)
- Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, He T, Shi C, Bedel O, McLean LR, Le-Strat F, Zhang Y, Marquette JP, Gao Q, Zhang B, Rak A, Hoffmann D, Rooney E, Vassort A, Englaro W, Li Y, Patel V, Adrian F, Gross S, Wiederschain D, Cheng H, Licht S. J Biol Chem 290 762-774 (2015)
- Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, Kaulfuss S, Panknin O, Zimmermann K, Toschi L, Neuhaus R, Haegebarth A, Rehwinkel H, Hess-Stumpp H, Bauser M, Bochtler T, Struys EA, Sharma A, Bakkali A, Geffers R, Araujo-Cruz MM, Thol F, Gabdoulline R, Ganser A, Ho AD, von Deimling A, Rippe K, Heuser M, Krämer A. Leukemia 31 2020-2028 (2017)
- Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. Cho YS, Levell JR, Liu G, Caferro T, Sutton J, Shafer CM, Costales A, Manning JR, Zhao Q, Sendzik M, Shultz M, Chenail G, Dooley J, Villalba B, Farsidjani A, Chen J, Kulathila R, Xie X, Dodd S, Gould T, Liang G, Heimbach T, Slocum K, Firestone B, Pu M, Pagliarini R, Growney JD. ACS Med Chem Lett 8 1116-1121 (2017)
- Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. Davis MI, Gross S, Shen M, Straley KS, Pragani R, Lea WA, Popovici-Muller J, DeLaBarre B, Artin E, Thorne N, Auld DS, Li Z, Dang L, Boxer MB, Simeonov A. J Biol Chem 289 13717-13725 (2014)
- 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. Wu F, Zhou C, Yao Y, Wei L, Feng Z, Deng L, Song Y. J Med Chem 59 253-263 (2016)
- Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. Wu F, Jiang H, Zheng B, Kogiso M, Yao Y, Zhou C, Li XN, Song Y. J Med Chem 58 6899-6908 (2015)
- IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status. Kessler J, Güttler A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D. Radiother Oncol 116 381-387 (2015)
- Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. Levell JR, Caferro T, Chenail G, Dix I, Dooley J, Firestone B, Fortin PD, Giraldes J, Gould T, Growney JD, Jones MD, Kulathila R, Lin F, Liu G, Mueller A, van der Plas S, Slocum K, Smith T, Terranova R, Touré BB, Tyagi V, Wagner T, Xie X, Xu M, Yang FS, Zhou LX, Pagliarini R, Cho YS. ACS Med Chem Lett 8 151-156 (2017)
- The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. Suijker J, Baelde HJ, Roelofs H, Cleton-Jansen AM, Bovée JV. Oncotarget 6 14832-14842 (2015)
- Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer. Brooks E, Wu X, Hanel A, Nguyen S, Wang J, Zhang JH, Harrison A, Zhang W. J Biomol Screen 19 1193-1200 (2014)
- Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. Wen H, Cho HR, Yun T, Kim H, Park CK, Lee SH, Choi SH, Park S. J Neurochem 132 183-193 (2015)
- Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. Zheng M, Sun W, Gao S, Luan S, Li D, Chen R, Zhang Q, Chen L, Huang J, Li H. Oncotarget 8 44255-44265 (2017)
- An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Verdura S, Cuyàs E, Lozano-Sánchez J, Bastidas-Velez C, Llorach-Parés L, Fernández-Arroyo S, Hernández-Aguilera A, Joven J, Nonell-Canals A, Bosch-Barrera J, Martin-Castillo B, Vellon L, Sanchez-Martinez M, Segura-Carretero A, Menendez JA. Carcinogenesis 40 27-40 (2019)
- Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Reinbold R, Hvinden IC, Rabe P, Herold RA, Finch A, Wood J, Morgan M, Staudt M, Clifton IJ, Armstrong FA, McCullagh JSO, Redmond J, Bardella C, Abboud MI, Schofield CJ. Nat Commun 13 4785 (2022)
- Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1. Law JM, Stark SC, Liu K, Liang NE, Hussain MM, Leiendecker M, Ito D, Verho O, Stern AM, Johnston SE, Zhang YL, Dunn GP, Shamji AF, Schreiber SL. ACS Med Chem Lett 7 944-949 (2016)
- Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP. Wu F, Hua Y, Kaochar S, Nie S, Lin YL, Yao Y, Wu J, Wu X, Fu X, Schiff R, Davis CM, Robertson M, Ehli EA, Coarfa C, Mitsiades N, Song Y. J Med Chem 63 4716-4731 (2020)
- Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1. Kim HJ, Choi BY, Keum YS. J Cancer Prev 20 78-83 (2015)
- Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. Zhao Q, Manning JR, Sutton J, Costales A, Sendzik M, Shafer CM, Levell JR, Liu G, Caferro T, Cho YS, Palermo M, Chenail G, Dooley J, Villalba B, Farsidjani A, Chen J, Dodd S, Gould T, Liang G, Slocum K, Pu M, Firestone B, Growney J, Heimbach T, Pagliarini R. ACS Med Chem Lett 9 746-751 (2018)
- Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer. Wu F, Cheng G, Yao Y, Kogiso M, Jiang H, Li XN, Song Y. Med Chem 14 715-724 (2018)
- Synthetic Derivatives of Ciclopirox are Effective Inhibitors of Cryptococcus neoformans. Lin J, Zangi M, Kumar TVNH, Shakar Reddy M, Reddy LVR, Sadhukhan SK, Bradley DP, Moreira-Walsh B, Edwards TC, O'Dea AT, Tavis JE, Meyers MJ, Donlin MJ. ACS Omega 6 8477-8487 (2021)
- 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation. Hu Y, Gao A, Liao H, Zhang M, Xu G, Gao L, Xu L, Zhou Y, Gao J, Ye Q, Li J. Arch Pharm (Weinheim) 351 e1800039 (2018)
- Comparative evaluation of new dihydropyrimidine and dihydropyridine derivatives perturbing mitotic spindle formation. Perużyńska M, Piotrowska K, Tkacz M, Kurzawski M, Struk Ł, Borzyszkowska A, Idzik TJ, Sośnicki JG, Droździk M. Future Med Chem 10 2395-2410 (2018)
- Crystal structure studies of NADP+ dependent isocitrate dehydrogenase from Thermus thermophilus exhibiting a novel terminal domain. Kumar SM, Pampa KJ, Manjula M, Abdoh MM, Kunishima N, Lokanath NK. Biochem Biophys Res Commun 449 107-113 (2014)
- Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2. Wang F, Li Z, Zhang T, Yan G, Hu M, Zhao L, Zhao Y, Chen Y. Chem Biol Drug Des 91 1087-1093 (2018)
- Discovery of a novel series of N-hydroxypyridone derivatives protecting astrocytes against hydrogen peroxide-induced toxicity via improved mitochondrial functionality. Singh S, Goo JI, Noh H, Lee SJ, Kim MW, Park H, Jalani HB, Lee K, Kim C, Kim WK, Ju C, Choi Y. Bioorg Med Chem 25 1394-1405 (2017)
- Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach. Juritz EI, Bascur JP, Almonacid DE, González-Nilo FD. Mol Diagn Ther 22 369-380 (2018)
- Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. Kogiso M, Qi L, Du Y, Braun FK, Zhang H, Huang LF, Guo L, Huang Y, Teo WY, Lindsay H, Zhao S, Injac SG, Liu Z, Mehta V, Tran D, Li F, Baxter PA, Su JM, Perlaky L, Parsons DW, Chintagumpala M, Adesina A, Song Y, Li XN. Transl Oncol 18 101368 (2022)
- Design, synthesis and biological evaluation of novel 5-hydroxy-2-methyl-4H-pyran-4-one derivatives as antiglioma agents. Li YB, Hou W, Lin H, Sun PH, Lin J, Chen WM. Medchemcomm 9 471-476 (2018)
- Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors. Liu S, Abboud M, Mikhailov V, Liu X, Reinbold R, Schofield CJ. J Med Chem 66 5279-5288 (2023)
- Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer. Das D, Karthik N, Taneja R. Subcell Biochem 100 523-555 (2022)